Clinical Trial Update: A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II multi-center trial evaluating 4SCAR19 CAR-T cells for relapsed or refractory B-cell malignancies; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Malignancies

Drugs mentioned

• 4SCAR19

Snippet

Sponsor: Shenzhen Geno-Immune Medical Institute | Conditions: B-cell Malignancies | Phase 1, Phase 2 | Status: RECRUITING